KR102563568B1 - 렙틴 수용체에 길항하는 항원-결합 단백질 - Google Patents

렙틴 수용체에 길항하는 항원-결합 단백질 Download PDF

Info

Publication number
KR102563568B1
KR102563568B1 KR1020197016377A KR20197016377A KR102563568B1 KR 102563568 B1 KR102563568 B1 KR 102563568B1 KR 1020197016377 A KR1020197016377 A KR 1020197016377A KR 20197016377 A KR20197016377 A KR 20197016377A KR 102563568 B1 KR102563568 B1 KR 102563568B1
Authority
KR
South Korea
Prior art keywords
antibody
lepr
amino acid
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197016377A
Other languages
English (en)
Korean (ko)
Other versions
KR20190075133A (ko
Inventor
제스퍼 그로마다
파나이이오티스 스테비스
주디스 알타레요스
Original Assignee
리제너론 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리제너론 파마슈티칼스 인코포레이티드 filed Critical 리제너론 파마슈티칼스 인코포레이티드
Publication of KR20190075133A publication Critical patent/KR20190075133A/ko
Application granted granted Critical
Publication of KR102563568B1 publication Critical patent/KR102563568B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020197016377A 2016-11-08 2017-11-08 렙틴 수용체에 길항하는 항원-결합 단백질 Active KR102563568B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662419062P 2016-11-08 2016-11-08
US62/419,062 2016-11-08
PCT/US2017/060690 WO2018089532A1 (en) 2016-11-08 2017-11-08 Antigen-binding proteins that antagonize leptin receptor

Publications (2)

Publication Number Publication Date
KR20190075133A KR20190075133A (ko) 2019-06-28
KR102563568B1 true KR102563568B1 (ko) 2023-08-04

Family

ID=60409473

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197016377A Active KR102563568B1 (ko) 2016-11-08 2017-11-08 렙틴 수용체에 길항하는 항원-결합 단백질

Country Status (29)

Country Link
US (3) US10550192B2 (enExample)
EP (2) EP4613772B1 (enExample)
JP (4) JP7042816B2 (enExample)
KR (1) KR102563568B1 (enExample)
CN (1) CN110167965A (enExample)
AU (2) AU2017359439B2 (enExample)
CA (1) CA3043365A1 (enExample)
CL (3) CL2019001263A1 (enExample)
CO (1) CO2019004672A2 (enExample)
DK (1) DK3538554T3 (enExample)
EA (1) EA201991075A1 (enExample)
ES (1) ES3040144T3 (enExample)
FI (1) FI3538554T3 (enExample)
HR (1) HRP20251165T1 (enExample)
HU (1) HUE073276T2 (enExample)
IL (2) IL266426B (enExample)
LT (1) LT3538554T (enExample)
MA (1) MA45801B1 (enExample)
MX (2) MX2019005397A (enExample)
MY (2) MY203682A (enExample)
PH (1) PH12019500988A1 (enExample)
PL (1) PL3538554T3 (enExample)
PT (1) PT3538554T (enExample)
RS (1) RS67214B1 (enExample)
SG (1) SG10201913470SA (enExample)
SI (1) SI3538554T1 (enExample)
SM (1) SMT202500327T1 (enExample)
UA (1) UA127678C2 (enExample)
WO (1) WO2018089532A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI824372B (zh) 2015-10-12 2023-12-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
MA45801B1 (fr) 2016-11-08 2021-11-30 Regeneron Pharma Protéines de liaison à l'antigène qui sont des antagonistes du récepteur de leptine
SG11202005146VA (en) 2017-12-18 2020-06-29 Regeneron Pharma Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof
SMT202500283T1 (it) 2018-04-06 2025-09-12 Regeneron Pharma Un anticorpo agonista del recettore della leptina da utilizzare per aumentare la massa ossea in un soggetto affetto da disfunzione metabolica o ipoleptinemia
WO2020016160A1 (en) * 2018-07-16 2020-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat neurological diseases
CN113195532B (zh) * 2018-12-18 2025-04-11 瑞泽恩制药公司 使用针对瘦素受体、gdf8和活化素a的拮抗剂增加体重和瘦肌肉质量的组合物和方法
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
KR20230038524A (ko) * 2020-07-17 2023-03-20 스미토모 세이카 가부시키가이샤 흡수체
BR112023004716A2 (pt) * 2020-09-15 2023-05-09 Regeneron Pharma Uso de agonistas de lepr para dor
CN118436632B (zh) * 2024-07-05 2024-08-30 四川大学华西第二医院 Teriflunomide在制备预防和/或治疗原发性纤毛不动综合征的药物中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997026335A1 (en) 1996-01-16 1997-07-24 The Rockefeller University Db, the receptor for leptin, nucleic acids encoding the receptor, and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451523B1 (en) 1994-09-14 2002-09-17 Interneuron Pharmaceuticals, Inc. Detection of a leptin receptor variant and methods for regulating obesity
US5912123A (en) 1994-09-14 1999-06-15 Progenitor, Inc. Detection of the leptin receptor in reproductive organs and methods for regulating reproductive biology
US5856098A (en) 1994-09-14 1999-01-05 Progenitor, Inc. Detection of a leptin receptor variant
US5643748A (en) 1994-09-14 1997-07-01 Progenitor, Inc. HU-B1.219, a novel human hematopoietin receptor
US6977240B1 (en) * 1995-11-27 2005-12-20 Millenium Pharmaceuticals, Inc. Methods of using the OB receptor antibodies to treat bodyweight disorders
US6482927B1 (en) 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
AU721129B2 (en) 1996-01-08 2000-06-22 Genentech Inc. WSX receptor and ligands
AU2476301A (en) 1996-01-16 2001-05-24 Rockefeller University, The DB the receptor for leptin nucleic acids encoding the receptor, and uses thereof
AU1833197A (en) 1996-01-18 1997-08-11 Progenitor, Inc. Detection of a leptin receptor variant and methods for regulating obesity
AU731685C (en) 1996-01-23 2002-08-22 Indevus Pharmaceuticals, Inc. Methods for using the obese gene and its gene product to stimulate hematopoietic development
US7067472B1 (en) 1996-06-04 2006-06-27 The Scripps Research Institute Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies
US5965521A (en) 1997-02-25 1999-10-12 Eli Lilly Company Pulsatile delivery of leptin receptor ligands
IL120733A0 (en) 1997-04-29 1997-08-14 Yeda Res & Dev Leptin as an inhibitor of cell proliferation
US6696411B1 (en) 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
AU767068B2 (en) 1999-06-11 2003-10-30 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of leptin activity
US20040253242A1 (en) 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
FR2852397B1 (fr) 2003-03-10 2005-04-29 Utilisation des genes leprotl 1 et ob-rgrp pour le criblage de composes actifs sur la prise ou la perte de poids ou le diabete d'un sujet humain ou animal.
ES2289235T3 (es) * 2003-08-21 2008-02-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Nuevo antagonista de leptina.
DE10353593A1 (de) * 2003-11-17 2005-06-23 Klinikum der Universität München Großhadern-Innenstadt Leptinantagonist und Verfahren zur quantitativen Messung von Leptin
US7863240B2 (en) 2004-10-08 2011-01-04 Enzo Therapeutics, Inc. Methods and uses of leptin in hepatocellular carcinoma
US8969291B2 (en) 2004-10-08 2015-03-03 Enzo Therapeutics, Inc. Methods for decreasing leptin levels or activity for treating inflammation
EP1812038A1 (en) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domain as leptin receptor antagonists
US7307142B2 (en) * 2004-11-26 2007-12-11 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Leptin antagonists
CA2606102C (en) 2005-04-26 2014-09-30 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
GB0715216D0 (en) 2007-08-03 2007-09-12 Asterion Ltd Leptin
US9221902B2 (en) 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
CN105859889B (zh) 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
RU2013139267A (ru) 2011-02-10 2015-03-20 Рош Гликарт Аг Улучшенная иммунотерапия
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
FI3366705T3 (fi) 2012-09-12 2023-07-28 Genzyme Corp Muuttuneen glykosylaation ja vähentyneen efektoritoiminnan omaavia fc:n sisältäviä polypeptidejä
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
RS57582B1 (sr) * 2013-02-20 2018-11-30 Regeneron Pharma Nehumane životinje sa modifikovanim sekvencama imunoglobulinskog teškog lanca
EP3108255B1 (en) 2014-02-18 2020-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway
TWI824372B (zh) 2015-10-12 2023-12-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
MA45801B1 (fr) 2016-11-08 2021-11-30 Regeneron Pharma Protéines de liaison à l'antigène qui sont des antagonistes du récepteur de leptine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997026335A1 (en) 1996-01-16 1997-07-24 The Rockefeller University Db, the receptor for leptin, nucleic acids encoding the receptor, and uses thereof

Also Published As

Publication number Publication date
MY203682A (en) 2024-07-12
KR20190075133A (ko) 2019-06-28
US20180127508A1 (en) 2018-05-10
JP7875904B2 (ja) 2026-06-18
EP4613772A3 (en) 2025-12-24
CL2020000549A1 (es) 2020-08-28
CL2019001263A1 (es) 2019-09-27
PH12019500988A1 (en) 2019-08-19
MA45801B1 (fr) 2021-11-30
EP3538554A1 (en) 2019-09-18
UA127678C2 (uk) 2023-11-29
JP2020504078A (ja) 2020-02-06
JP2023093753A (ja) 2023-07-04
LT3538554T (lt) 2025-10-10
CN110167965A (zh) 2019-08-23
FI3538554T3 (fi) 2025-09-24
CL2020001023A1 (es) 2020-10-09
IL266426A (en) 2019-06-30
CA3043365A1 (en) 2018-05-17
WO2018089532A1 (en) 2018-05-17
JP2022031969A (ja) 2022-02-22
RS67214B1 (sr) 2025-10-31
JP7042816B2 (ja) 2022-03-28
IL272358A (en) 2020-03-31
AU2017359439A1 (en) 2019-05-23
US20230235068A1 (en) 2023-07-27
AU2017359439B2 (en) 2024-11-28
MY191256A (en) 2022-06-10
US20200123264A1 (en) 2020-04-23
US10550192B2 (en) 2020-02-04
HUE073276T2 (hu) 2026-01-28
EA201991075A1 (ru) 2019-10-31
MA45801A1 (fr) 2020-07-29
EP3538554B1 (en) 2025-08-13
PT3538554T (pt) 2025-09-01
MX2023011233A (es) 2023-10-03
MX2019005397A (es) 2019-10-09
US11535675B2 (en) 2022-12-27
AU2025201454A1 (en) 2025-04-10
ES3040144T3 (en) 2025-10-28
IL272358B (en) 2022-02-01
PL3538554T3 (pl) 2025-10-27
JP2024109952A (ja) 2024-08-14
DK3538554T3 (da) 2025-09-08
JP7611292B2 (ja) 2025-01-09
IL266426B (en) 2020-11-30
SMT202500327T1 (it) 2025-11-10
SG10201913470SA (en) 2020-03-30
EP4613772A2 (en) 2025-09-10
HRP20251165T1 (hr) 2025-11-21
EP4613772B1 (en) 2026-07-22
CO2019004672A2 (es) 2019-07-31
SI3538554T1 (sl) 2025-10-30

Similar Documents

Publication Publication Date Title
US20250051465A1 (en) Antigen-binding proteins that activate the leptin receptor
US20230235068A1 (en) Antigen-binding proteins that antagonize leptin receptor
KR101859911B1 (ko) 사람 ｇｄｆ８에 대한 항체
DK2475684T3 (en) HUMAN HIGH-EFFICIENCY ANTIBODIES AGAINST HUMAN PROTEASE-ACTIVATED RECEPTOR-2
DK2809681T3 (en) ANTI-ASIC1 antibodies and uses thereof
KR20180070604A (ko) 항-lag3 항체 및 그 사용
KR20150041664A (ko) GFRα3에 대한 인간 항체 및 이것의 사용 방법
PH12014501730B1 (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
EA040524B1 (ru) Антигенсвязывающие белки, которые проявляют антагонизм в отношении лептинового рецептора

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4